Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618393 · ClinicalTrials.gov registry record · Phase 1
A Study of EMB-02 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Shanghai EpimAb Biotherapeutics Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04618393 is a Phase 1 study that was terminated before completion, run by Shanghai EpimAb Biotherapeutics Co.. The registered enrollment target is 47 participants.
The verdict
NCT04618393, a Phase 1 study, was terminated before completion, sponsored by Shanghai EpimAb Biotherapeutics Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be assessed.
Interventions
- BIOLOGICAL EMB-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04618393
The ClinicalTrials.gov registry entry for NCT04618393 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai EpimAb Biotherapeutics Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMB-02 is the first listed.
NCT04618393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04618393 about?
NCT04618393 is a clinical study titled "A Study of EMB-02 in Participants With Advanced Solid Tumors". The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be asses...
What is the current status of trial NCT04618393?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2021-03-11. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT04618393?
The interventions under investigation include: EMB-02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04618393?
This trial is sponsored by Shanghai EpimAb Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.